re: Ann: Cellestis Limited Announces Improved... Cellestis has always marketed the QFT as a test for latent TB. Any recommendation by the WHO against using IGRA tests for active TB will have no impact on Cellestis or the growth in sales for our latent TB test.
In short, it is not a good reason to consider selling our share in the company to Qiagen for such a low price.
- Forums
- ASX - By Stock
- CST
- Ann: Cellestis Limited Announces Improved Proposa
Ann: Cellestis Limited Announces Improved Proposa, page-20
Featured News
Add CST (ASX) to my watchlist
|
|||||
Last
7.1¢ |
Change
0.002(2.90%) |
Mkt cap ! $17.17M |
Open | High | Low | Value | Volume |
7.1¢ | 7.1¢ | 7.0¢ | $10.46K | 147.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 63600 | 7.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 179999 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 63600 | 0.070 |
1 | 29850 | 0.067 |
2 | 17521 | 0.066 |
1 | 45000 | 0.065 |
1 | 50000 | 0.061 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 179999 | 2 |
0.075 | 207566 | 2 |
0.080 | 2500 | 1 |
0.085 | 7000 | 1 |
0.098 | 50000 | 1 |
Last trade - 15.42pm 12/07/2024 (20 minute delay) ? |
Featured News
CST (ASX) Chart |